Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No-effect level in the mutagenic activity of the drug cyproterone acetate in rat liver. Part II. Multiple dose treatment.

Mutation research - 4 Jun 2004

Topinka Jan, Oesterle Doris, Reimann Roland, Wolff Thomas

Abstract excerpt

In order to probe for the existence of a no-effect levels for mutations induced by multiple dose treatment with cyproterone acetate (CPA), female lacI-transgenic Big Blue rats were treated daily for 3 weeks with oral doses of 5.0, 1.0 or 0.2mg/kg CPA b.w., respectively. The dose of 5mg/kg CPA b.w. ineffective as a single dose (see part I) increased the mutation frequency by 2.5-fold. Daily treatment with 1.0 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animals, Genetically Modified
Share to Cell Division

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Adducts

Share to Dose-Response Relationship, Drug

Share to Mutagens

Share to Rats, Inbred F344

Share to S Phase

Source

Identifiers

PMID: 15135644
DOI: 10.1016/j.mrfmmm.2004.02.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No-effect level in the mutagenic activity of the drug cyproterone acetate in rat liver. Part II. Multiple dose treatment.PMID 15135644Read ↗

No-effect level in the mutagenic activity of the drug cyproterone acetate in rat liver. Part I. Single dose treatment.Semantic proximity Read ↗

Dose dependent induction of DNA adducts, gene mutations, and cell proliferation by the antiandrogenic drug cyproterone acetate in rat liver.Semantic proximity Read ↗

Cyproterone acetate: a genotoxic carcinogen?Semantic proximity Read ↗

[Genotoxicity assessment of 2-ethylhexyl acrylate using an in vivo Pig-a gene mutation assay integrated system].Semantic proximity Read ↗

Absence of in vivo genotoxicity of 3-monochloropropane-1,2-diol and associated fatty acid esters in a 4-week comprehensive toxicity study using F344 gpt delta rats.Semantic proximity Read ↗

Use of early phenotypic in vivo markers to assess human relevance of an unusual rodent non-genotoxic carcinogen in vitro.Semantic proximity Read ↗

Mutant frequency of lacI in transgenic mice following benzo[a]pyrene treatment and partial hepatectomy.Semantic proximity Read ↗

Compensatory erythropoiesis has no impact on the outcome of the in vivo Pig-a mutation assay in rats following treatment with the haemolytic agent 2-butoxyethanol.Semantic proximity Read ↗

Evidence of clonal proliferation of hepatocytes after carbon-tetrachloride-induced hepatic injury in PGK-1 mosaic mice.Semantic proximity Read ↗

Pyrene did not induce gene mutation in red blood cell Pig-a assay and PIGRET assay in rats.Semantic proximity Read ↗

Application of humanized mice to toxicology studies: Evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR)Semantic proximity Read ↗

Effect of mitogenic or regenerative cell proliferation on lacz mutant frequency in the liver of MutaTMMice treated with 5, 9-dimethyldibenzo[c,g]carbazole.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.